- Chemed Corporation recently reported first-quarter 2026 results, with net income of US$66.3 million versus US$71.76 million a year earlier, and continued its long-running buyback by repurchasing 500,000 shares for US$197.7 million.
- An interesting nuance is that, despite softer earnings, Chemed has now retired about 71.73% of the shares authorized under its 2011 repurchase program, underscoring management’s ongoing commitment to returning capital.
- We’ll now examine how this combination of slightly lower earnings and continued share repurchases may influence Chemed’s existing investment narrative.
Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
Chemed Investment Narrative Recap
To own Chemed, you generally need to be comfortable with a story built around VITAS’ hospice footprint, exposure to Medicare rules, and Roto Rooter’s ability to manage costs and demand. The latest quarter’s modestly lower earnings alongside continued buybacks do not materially change the near term picture, where the key catalyst remains progress on Medicare Cap management and the biggest risk is ongoing pressure on Roto Rooter margins from weaker demand and higher acquisition costs.
The recent buyback update is especially relevant here. Chemed retired 500,000 shares in the first quarter of 2026 and has now used 71.73% of its long standing authorization, even as net income softened. That reduction in share count sits alongside management’s 2026 EPS guidance and existing Medicare and Roto Rooter headwinds, which means investors may want to watch how repurchases interact with any future changes in operating performance.
Yet even with these supports, investors should be aware that Roto Rooter’s weaker residential demand and higher paid lead costs could still...
Read the full narrative on Chemed (it's free!)
Chemed's narrative projects $3.1 billion revenue and $385.1 million earnings by 2029. This requires 6.5% yearly revenue growth and about a $125 million earnings increase from $259.8 million today.
Uncover how Chemed's forecasts yield a $443.00 fair value, a 4% upside to its current price.
Exploring Other Perspectives
The most optimistic analysts were penciling in about US$3.0 billion of revenue and US$397.1 million of earnings by 2029, which is far more upbeat than consensus and leans heavily on smoother Medicare Cap exposure and stronger hospice margins. With Q1 2026 earnings down year on year, you should consider how that rosier view of VITAS’ admission mix shift might evolve as new data emerges.
Explore 5 other fair value estimates on Chemed - why the stock might be worth just $443.00!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Chemed research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Chemed research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Chemed's overall financial health at a glance.
Looking For Alternative Opportunities?
Every day counts. These free picks are already gaining attention. See them before the crowd does:
- AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com